{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:34:37Z","timestamp":1795034077624,"version":"4.10.2"},"reference-count":121,"publisher":"American Society of Hematology","issue":"15","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Severe aplastic anemia (SAA) is a rare hematologic condition for which there is no clear management algorithm. A panel of 11 experts on adult and pediatric aplastic anemia was assembled and, using the RAND\/University of California, Los Angeles modified Delphi panel method, evaluated &amp;gt;600 varying patient care scenarios to develop clinical recommendations for the initial and subsequent management of patients of all ages with SAA. Here, we present the panel\u2019s recommendations to rule out inherited bone marrow failure syndromes, on supportive care before and during first-line therapy, and on first-line (initial management) and second-line (subsequent management) therapy of acquired SAA, focusing on when transplant vs medical therapy is most appropriate. These recommendations represent the consensus of 11 experts informed by published literature and experience. They are intended only as general guidance for experienced clinicians who treat patients with SAA and are in no way intended to supersede individual physician and patient decision making. Current and future research should validate this consensus using clinical data. Once validated, we hope these expert panel recommendations will improve outcomes for patients with SAA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011642","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T17:59:20Z","timestamp":1714154360000},"page":"3946-3960","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Modified Delphi panel consensus recommendations for management of severe aplastic anemia"],"prefix":"10.1182","volume":"8","author":[{"given":"Daria V.","family":"Babushok","sequence":"first","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[{"name":"2Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4485-6025","authenticated-orcid":false,"given":"Carlos M.","family":"de Castro","sequence":"additional","affiliation":[{"name":"3Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-2368","authenticated-orcid":false,"given":"Zora R.","family":"Rogers","sequence":"additional","affiliation":[{"name":"4Division of Pediatric Hematology-Oncology, University of Texas, Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Beenhouwer","sequence":"additional","affiliation":[{"name":"5Partnership for Health Analytic Research, Beverly Hills, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Broder","sequence":"additional","affiliation":[{"name":"5Partnership for Health Analytic Research, Beverly Hills, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Fanning","sequence":"additional","affiliation":[{"name":"6Prisma Health Cancer Institute, University of South Carolina, Greenville, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah N.","family":"Gibbs","sequence":"additional","affiliation":[{"name":"5Partnership for Health Analytic Research, Beverly Hills, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi","family":"Hanna","sequence":"additional","affiliation":[{"name":"7Department of Pediatric Hematology Oncology and Bone Marrow Transplantation, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"8Translational Hematology and Oncology Research Department, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-7839","authenticated-orcid":false,"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[{"name":"9Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas K.","family":"Tantravahi","sequence":"additional","affiliation":[{"name":"10Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6638-9643","authenticated-orcid":false,"given":"Marcin W.","family":"Wlodarski","sequence":"additional","affiliation":[{"name":"11Department of Hematology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6035-2815","authenticated-orcid":false,"given":"Irina","family":"Yermilov","sequence":"additional","affiliation":[{"name":"5Partnership for Health Analytic Research, Beverly Hills, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4984-7751","authenticated-orcid":false,"given":"Bhumika J.","family":"Patel","sequence":"additional","affiliation":[{"name":"6Prisma Health Cancer Institute, University of South Carolina, Greenville, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"issue":"4","key":"2024081315054528800_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3324\/haematol.12855","article-title":"The epidemiology of acquired aplastic anemia - PubMed","volume":"93","author":"Young","year":"2008","journal-title":"Haematologica"},{"issue":"12","key":"2024081315054528800_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-017-0511-z","article-title":"Diagnosis and treatment of Aplastic Anemia","volume":"18","author":"Peslak","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"suppl 1","key":"2024081315054528800_bib3","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/j.bbmt.2009.09.013","article-title":"Aplastic anemia: pathophysiology and treatment","volume":"16","author":"Young","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2024081315054528800_bib4","doi-asserted-by":"crossref","first-page":"e977","DOI":"10.1097\/HS9.0000000000000977","article-title":"Single-cell RNA sequencing reveals novel cellular factors for response to immunosuppressive therapy in aplastic anemia","volume":"7","author":"Jang","year":"2023","journal-title":"Hemasphere"},{"key":"2024081315054528800_bib5","doi-asserted-by":"crossref","first-page":"103026","DOI":"10.1016\/j.jaut.2023.103026","article-title":"Single-cell analysis highlights a population of Th17-polarized CD4+ na\u00efve T cells showing IL6\/JAK3\/STAT3 activation in pediatric severe aplastic anemia","volume":"136","author":"Zhang","year":"2023","journal-title":"J\u00a0Autoimmun"},{"issue":"6","key":"2024081315054528800_bib6","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1007\/s10238-023-01017-0","article-title":"STAT1 overexpression triggers aplastic anemia: a pilot study unravelling novel pathogenetic insights in bone marrow failure","volume":"23","author":"Solimando","year":"2023","journal-title":"Clin Exp Med"},{"issue":"3","key":"2024081315054528800_bib7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ejh.13908","article-title":"Bone marrow expression of CD68\/CD163 macrophages, IL-17 and FOXP3 cells in aplastic anemia and their relation to prognosis","volume":"110","author":"Vaht","year":"2023","journal-title":"Eur J Haematol"},{"issue":"1","key":"2024081315054528800_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41375-022-01723-w","article-title":"Molecular landscape of immune pressure and escape in aplastic anemia","volume":"37","author":"Pagliuca","year":"2023","journal-title":"Leukemia"},{"issue":"22","key":"2024081315054528800_bib9","doi-asserted-by":"crossref","first-page":"e163040","DOI":"10.1172\/jci.insight.163040","article-title":"Pathogenicity and impact of HLA class I alleles in aplastic anemia patients of different ethnicities","volume":"7","author":"Olson","year":"2022","journal-title":"JCI Insight"},{"issue":"12","key":"2024081315054528800_bib10","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.3324\/haematol.2021.280292","article-title":"Impaired immunosuppressive role of myeloid-derived suppressor cells in acquired aplastic anemia","volume":"107","author":"Dong","year":"2022","journal-title":"Haematologica"},{"key":"2024081315054528800_bib11","doi-asserted-by":"crossref","first-page":"790990","DOI":"10.3389\/fgene.2021.790990","article-title":"Multi-omics profiling identifies pathways associated with CD8+ T-cell activation in severe aplastic anemia","volume":"12","author":"You","year":"2021","journal-title":"Front Genet"},{"issue":"26","key":"2024081315054528800_bib12","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood.2021012895","article-title":"HLA associations, somatic loss of HLA expression, and clinical outcomes in immune aplastic anemia","volume":"138","author":"Zaimoku","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2024081315054528800_bib13","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood.2019001347","article-title":"Treg sensitivity to FasL and relative IL-2 deprivation drive idiopathic aplastic anemia immune dysfunction","volume":"136","author":"Lim","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2024081315054528800_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ajhg.2020.01.004","article-title":"Genome-wide association study identifies HLA-DPB1 as a significant risk factor for severe aplastic anemia","volume":"106","author":"Savage","year":"2020","journal-title":"Am J Hum Genet"},{"issue":"9","key":"2024081315054528800_bib15","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41375-022-01654-6","article-title":"Anti-COX-2 autoantibody is a novel biomarker of immune aplastic anemia","volume":"36","author":"Kelkka","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"2024081315054528800_bib16","doi-asserted-by":"crossref","first-page":"a005769","DOI":"10.1101\/mcs.a005769","article-title":"Aplastic anemia in a patient with CVID due to NFKB1 haploinsufficiency","volume":"6","author":"Sklarz","year":"2020","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"15","key":"2024081315054528800_bib17","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/bloodadvances.2022008224","article-title":"System-level immune monitoring reveals new pathophysiological features in hepatitis-associated aplastic anemia","volume":"7","author":"Braudeau","year":"2023","journal-title":"Blood Adv"},{"key":"2024081315054528800_bib18","author":"Kaufman","year":"1991"},{"issue":"8","key":"2024081315054528800_bib19","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.V75.8.1646.1646","article-title":"Epidemiology of aplastic anemia in France: a prospective multicentric study. the French Cooperative Group for epidemiological study of aplastic Anemia","volume":"75","author":"Mary","year":"1990","journal-title":"Blood"},{"issue":"6","key":"2024081315054528800_bib20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0145-2126(88)90111-7","article-title":"Aplastic anaemia incidence in parts of the United Kingdom in 1985","volume":"12","author":"Cartwright","year":"1988","journal-title":"Leuk Res"},{"issue":"4","key":"2024081315054528800_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/adc.74.4.319","article-title":"Severe aplastic anaemia in the Nordic countries: a population based study of incidence, presentation, course, and outcome","volume":"74","author":"Clausen","year":"1996","journal-title":"Arch Dis Child"},{"issue":"4","key":"2024081315054528800_bib22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ajh.10232","article-title":"Aplastic anemia in Brazil: incidence and risk factors","volume":"71","author":"Maluf","year":"2002","journal-title":"Am J Hematol"},{"issue":"12","key":"2024081315054528800_bib23","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1182\/bloodadvances.2021004345","article-title":"Approach to the diagnosis of aplastic anemia","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"key":"2024081315054528800_bib24","article-title":"A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia","volume":"53(3):504-14","author":"Camitta","year":"1979","journal-title":"Blood"},{"issue":"2","key":"2024081315054528800_bib25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5045\/kjh.2012.47.2.126","article-title":"Should we still use Camitta\u2019s criteria for severe aplastic anemia?","volume":"47","author":"Yoon","year":"2012","journal-title":"Korean J Hematol"},{"issue":"11","key":"2024081315054528800_bib26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM198203183061105","article-title":"Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis","volume":"306","author":"Camitta","year":"1982","journal-title":"N Engl J Med"},{"issue":"12","key":"2024081315054528800_bib27","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1056\/NEJM198203253061204","article-title":"Aplastic anmiea: second of two parts: pathogenesis, diagnosis, treatment and prognosis","volume":"306","author":"Camitta","year":"1982","journal-title":"N Engl J Med"},{"issue":"2","key":"2024081315054528800_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/bjh.13853","article-title":"Guidelines for the diagnosis and management of adult aplastic anaemia","volume":"172","author":"Killick","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"2024081315054528800_bib29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41409-019-0773-0","article-title":"Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party","volume":"55","author":"Prata","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024081315054528800_bib30","doi-asserted-by":"crossref","first-page":"e13810","DOI":"10.1111\/ctr.13810","article-title":"Comparable survival outcome between transplantation from haploidentical donor and matched related donor or unrelated donor for severe aplastic anemia patients aged 40 years and older: a retrospective multicenter cohort study","volume":"34","author":"Zhang","year":"2020","journal-title":"Clin Transplant"},{"issue":"8","key":"2024081315054528800_bib31","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/bloodadvances.2020001729","article-title":"Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide","volume":"4","author":"DeZern","year":"2020","journal-title":"Blood Adv"},{"issue":"10","key":"2024081315054528800_bib32","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/s41409-020-0897-2","article-title":"Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT)","volume":"55","author":"ElGohary","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024081315054528800_bib33","doi-asserted-by":"crossref","first-page":"331.e1","DOI":"10.1016\/j.jtct.2021.01.018","article-title":"Haploidentical transplantation with modified post-transplantation cyclophosphamide for patients with primary aplastic anemia: a multicenter experience","volume":"27","author":"Li","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2024081315054528800_bib34","doi-asserted-by":"crossref","first-page":"429.e1","DOI":"10.1016\/j.jtct.2021.02.014","article-title":"Haploidentical peripheral stem cell transplantation for young patients with severe aplastic anemia using post-transplantation cyclophosphamide and methotrexate","volume":"27","author":"Yang","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2024081315054528800_bib35","doi-asserted-by":"crossref","first-page":"105.e1","DOI":"10.1016\/j.jtct.2021.10.006","article-title":"Upfront alternative donor transplant versus immunosuppressive therapy in patients with severe aplastic anemia who lack a fully HLA-matched related donor: systematic review and meta-analysis of retrospective studies, on behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"28","author":"Alotaibi","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"2024081315054528800_bib36","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(22)00206-X","article-title":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial","volume":"9","author":"DeZern","year":"2022","journal-title":"Lancet Haematol"},{"issue":"9","key":"2024081315054528800_bib37","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.scib.2022.01.024","article-title":"Long-term follow-up of haploidentical transplantation in relapsed\/refractory severe aplastic anemia: a multicenter prospective study","volume":"67","author":"Xu","year":"2022","journal-title":"Sci Bull (Beijing)"},{"issue":"7","key":"2024081315054528800_bib38","doi-asserted-by":"crossref","first-page":"463.e1","DOI":"10.1016\/j.jtct.2023.04.015","article-title":"Prospective study of a modified post-transplantation cyclophosphamide regimen for severe aplastic anemia patients with HLA-haploidentical transplantation","volume":"29","author":"Wu","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"10","key":"2024081315054528800_bib39","doi-asserted-by":"crossref","first-page":"621.e1","DOI":"10.1016\/j.jtct.2023.07.011","article-title":"Haploidentical hematopoietic stem cell transplantation in pediatric patients with acquired hypocellular bone marrow failure","volume":"29","author":"Quintero","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2024081315054528800_bib40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12185-022-03506-6","article-title":"Allogeneic bone marrow transplantation for aplastic anemia","volume":"119","author":"Storb","year":"2024","journal-title":"Int J Hematol"},{"key":"2024081315054528800_bib41","article-title":"Horse versus rabbit antithymocyte globulin in acquired aplastic anemia","volume":"365(5):430-8","author":"Scheinberg","year":"2011","journal-title":"N Engl J Med"},{"issue":"16","key":"2024081315054528800_bib42","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic Anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2024081315054528800_bib43","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1002\/cncr.31658","article-title":"Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia","volume":"124","author":"Assi","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"2024081315054528800_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2109965","article-title":"Eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2024081315054528800_bib45","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2024081315054528800_bib46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1200931","article-title":"Eltrombopag and improved hematopoiesis in refractory aplastic anemia","volume":"367","author":"Olnes","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024081315054528800_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-023-00377-3","article-title":"Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study","volume":"12","author":"Yang","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"2024081315054528800_bib48","doi-asserted-by":"crossref","first-page":"20406207231191310","DOI":"10.1177\/20406207231191310","article-title":"Comparison of eltrombopag and avatrombopag in the treatment of refractory\/relapsed aplastic anemia: a single-center retrospective study in China","volume":"14","author":"Zhang","year":"2023","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"2024081315054528800_bib49","doi-asserted-by":"crossref","first-page":"2224044","DOI":"10.1080\/07853890.2023.2224044","article-title":"Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory\/relapsed\/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial","volume":"55","author":"Wan","year":"2023","journal-title":"Ann Med"},{"issue":"6","key":"2024081315054528800_bib50","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/bjh.17403","article-title":"Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries","volume":"194","author":"Scheinberg","year":"2021","journal-title":"Br J Haematol"},{"key":"2024081315054528800_bib51","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMra1413485","article-title":"Aplastic Anemia","volume":"379(17)","author":"Young","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"2024081315054528800_bib52","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/0272989X211028236","article-title":"Reference case methods for expert elicitation in health care decision making","volume":"42","author":"Bojke","year":"2022","journal-title":"Med Decis Making"},{"issue":"8","key":"2024081315054528800_bib53","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.1995.03530080048040","article-title":"Validity of criteria used for detecting underuse of coronary revascularization","volume":"274","author":"Kravitz","year":"1995","journal-title":"JAMA"},{"issue":"5","key":"2024081315054528800_bib54","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s12350-017-0917-9","article-title":"ACC\/AATS\/AHA\/ASE\/ASNC\/SCAI\/SCCT\/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease : a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons","volume":"24","author":"Patel","year":"2017","journal-title":"J\u00a0Nucl Cardiol"},{"issue":"2","key":"2024081315054528800_bib55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.amjcard.2015.03.057","article-title":"Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial)","volume":"116","author":"Bradley","year":"2015","journal-title":"Am J Cardiol"},{"issue":"26","key":"2024081315054528800_bib56","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199806253382607","article-title":"The reproducibility of a method to identify the overuse and underuse of medical procedures","volume":"338","author":"Shekelle","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2024081315054528800_bib57","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM200103013440906","article-title":"Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization","volume":"344","author":"Hemingway","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"2024081315054528800_bib58","unstructured":"Sch\u00fcnemann\n              H\n            , Bro\u017cekJ, GuyattG Oxman. GRADE handbook: handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. Accessed 12 March 2024. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html."},{"issue":"9","key":"2024081315054528800_bib59","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2105\/AJPH.74.9.979","article-title":"Consensus methods: characteristics and guidelines for use","volume":"74","author":"Fink","year":"1984","journal-title":"Am J Public Health"},{"key":"2024081315054528800_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040620721998126","article-title":"Current evidence and the emerging role of eltrombopag in severe aplastic anemia","volume":"12","author":"Drexler","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"2024081315054528800_bib61","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjh.14510","article-title":"Recent advances in understanding clonal haematopoiesis in aplastic anaemia","volume":"177","author":"Stanley","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"2024081315054528800_bib62","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1414799","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Yoshizato","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2024081315054528800_bib63","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3324\/haematol.13829","article-title":"Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study","volume":"94","author":"Scheinberg","year":"2009","journal-title":"Haematologica"},{"issue":"19","key":"2024081315054528800_bib64","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJM199105093241901","article-title":"Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group","volume":"324","author":"Frickhofen","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024081315054528800_bib65","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2002-04-1134","article-title":"Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia","volume":"101","author":"Frickhofen","year":"2003","journal-title":"Blood"},{"issue":"17","key":"2024081315054528800_bib66","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1182\/blood-2010-08-304071","article-title":"A\u00a0randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation","volume":"117","author":"Tichelli","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2024081315054528800_bib67","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood-2011-05-352328","article-title":"Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia","volume":"119","author":"Scheinberg","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2024081315054528800_bib68","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3324\/haematol.2011.042622","article-title":"Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia","volume":"96","author":"Afable","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"2024081315054528800_bib69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJM198301203080301","article-title":"Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized Trial","volume":"308","author":"Champlin","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024081315054528800_bib70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1182\/blood.V66.1.184.184","article-title":"Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? a prospective randomized trial","volume":"66","author":"Champlin","year":"1985","journal-title":"Blood"},{"issue":"2","key":"2024081315054528800_bib71","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.V87.2.491.bloodjournal872491","article-title":"Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation","volume":"87","author":"Brodsky","year":"1996","journal-title":"Blood"},{"issue":"9241","key":"2024081315054528800_bib72","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/S0140-6736(00)03126-3","article-title":"High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial","volume":"356","author":"Tisdale","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"2024081315054528800_bib73","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1046\/j.1365-2141.2002.03947.x","article-title":"Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia","volume":"119","author":"Gluckman","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"2024081315054528800_bib74","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3324\/haematol.2019.222562","article-title":"Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation","volume":"105","author":"Tichelli","year":"2020","journal-title":"Haematologica"},{"issue":"11","key":"2024081315054528800_bib75","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","article-title":"How I treat acquired aplastic anemia","volume":"129","author":"Bacigalupo","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024081315054528800_bib76","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.22.00710","article-title":"Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria","volume":"41","author":"Gurnari","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024081315054528800_bib77","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"2024081315054528800_bib78","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41375-022-01636-8","article-title":"Predictors of clonal evolution and myeloid neoplasia following immunosuppressive therapy in severe aplastic anemia","volume":"36","author":"Groarke","year":"2022","journal-title":"Leukemia"},{"issue":"17","key":"2024081315054528800_bib79","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1182\/blood-2014-05-574889","article-title":"Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome","volume":"124","author":"Kulasekararaj","year":"2014","journal-title":"Blood"},{"issue":"16","key":"2024081315054528800_bib80","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1182\/bloodadvances.2021004201","article-title":"The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis","volume":"5","author":"Shah","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2024081315054528800_bib81","doi-asserted-by":"crossref","first-page":"281.e1","DOI":"10.1016\/j.jtct.2023.11.013","article-title":"HLA class I allele loss and bone marrow transplantation outcomes in immune aplastic anemia","volume":"30","author":"Zaimoku","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2024081315054528800_bib82","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/bloodadvances.2021006044","article-title":"Minor PNH clones do not distinguish inherited bone marrow failure syndromes from immune-mediated aplastic anemia","volume":"6","author":"Narita","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2024081315054528800_bib83","doi-asserted-by":"crossref","first-page":"E2358","DOI":"10.1073\/pnas.1720427115","article-title":"Diagnostic utility of telomere length testing in a hospital-based setting","volume":"115","author":"Alder","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2024081315054528800_bib84","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000366251","article-title":"Comparison of chromosome breakage in non-mosaic and mosaic patients with Fanconi anemia, relatives, and patients with other inherited bone marrow failure syndromes","volume":"144","author":"Fargo","year":"2014","journal-title":"Cytogenet Genome Res"},{"issue":"5","key":"2024081315054528800_bib85","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1073\/pnas.051609898","article-title":"Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells","volume":"98","author":"Gregory","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2024081315054528800_bib86","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2024081315054528800_bib87","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/bmt.2012.220","article-title":"Supportive care in severe and very severe aplastic anemia","volume":"48","author":"H\u00f6chsmann","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2024081315054528800_bib88","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/ehm.11.11","article-title":"Clinical management of aplastic anemia","volume":"4","author":"DeZern","year":"2011","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2024081315054528800_bib89","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/cid\/ciq245","article-title":"Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades","volume":"52","author":"Valdez","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"30","key":"2024081315054528800_bib90","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"2024081315054528800_bib91","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2024081315054528800_bib92","unstructured":"US National Library of Medicine\n          . A trial comparing unrelated donor BMT with IST for pediatric and young adult patients with severe aplastic anemia (TransIT, BMT CTN 2202) (TransIT). Accessed 12 March 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05600426."},{"issue":"25","key":"2024081315054528800_bib93","first-page":"3031","article-title":"Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia","volume":"141","author":"DeZern","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2024081315054528800_bib94","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01378.x","article-title":"Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia","volume":"84","author":"Chang","year":"2010","journal-title":"Eur J Haematol"},{"issue":"4","key":"2024081315054528800_bib95","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/bjh.12661","article-title":"Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two-centre prospective study","volume":"164","author":"Kulagin","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"2024081315054528800_bib96","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1365-2141.2008.07450.x","article-title":"Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia","volume":"144","author":"Scheinberg","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"2024081315054528800_bib97","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12185-016-2009-z","article-title":"Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia","volume":"104","author":"Narita","year":"2016","journal-title":"Int J Hematol"},{"issue":"11","key":"2024081315054528800_bib98","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/s41375-021-01190-9","article-title":"Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia","volume":"35","author":"Fattizzo","year":"2021","journal-title":"Leukemia"},{"key":"2024081315054528800_bib99","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/9781444303537.ch30","volume-title":"Thomas\u2019 Hematopoietic Cell Transplantation","author":"Blume","year":"2009","edition":"1st ed."},{"key":"2024081315054528800_bib100","first-page":"349","volume-title":"Thomas\u2019 Hematopoietic Cell Transplantation: Stem Cell Transplantation","author":"Scott","year":"2016","edition":"5th ed."},{"issue":"29","key":"2024081315054528800_bib101","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2013.53.8157","article-title":"Comorbidity-Age Index: A\u00a0clinical measure of biologic age before allogeneic hematopoietic cell transplantation","volume":"32","author":"Sorror","year":"2014  10","journal-title":"J. Clin. Oncol"},{"issue":"11","key":"2024081315054528800_bib102","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1080\/14712598.2016.1229773","article-title":"Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation","volume":"16","author":"Fedele","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"2024081315054528800_bib103","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2017-09-746420","article-title":"Frailty and the management of hematologic malignancies","volume":"131","author":"Abel","year":"2018","journal-title":"Blood"},{"issue":"15","key":"2024081315054528800_bib104","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","article-title":"How I assess comorbidities before hematopoietic cell transplantation","volume":"121","author":"Sorror","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2024081315054528800_bib105","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"1","key":"2024081315054528800_bib106","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.2021012130","article-title":"Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study","volume":"139","author":"Patel","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2024081315054528800_bib107","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/bmt.2012.222","article-title":"on behalf of the Severe Aplastic Anemia\u2013Working Party of the EBMT. Front-line immunosuppressive treatment of acquired aplastic anemia","volume":"48","author":"Dufour","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2024081315054528800_bib108","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2008.002329","article-title":"Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?","volume":"94","author":"Passweg","year":"2009","journal-title":"Haematologica"},{"issue":"1","key":"2024081315054528800_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.2021014046","article-title":"Eltrombopag: a springboard to early responses in SAA","volume":"139","author":"Babushok","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2024081315054528800_bib110","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/bloodadvances.2023010959","article-title":"Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2\/3 study","volume":"8","author":"Mitani","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2024081315054528800_bib111","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bjh.17190","article-title":"Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II\/III, multicentre, open-label study","volume":"192","author":"Jang","year":"2021","journal-title":"Br J Haematol"},{"issue":"11","key":"2024081315054528800_bib112","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(19)30153-X","article-title":"Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial","volume":"6","author":"Lee","year":"2019","journal-title":"Lancet Haematol"},{"key":"2024081315054528800_bib113","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/01.HS9.0000846192.06541.42","article-title":"P827: efficacy and safety of romiplostim added to immunosuppressive therapy as a first-line treatment in patients with aplastic anemia: a phase 2\/3 clinical trial","volume":"6(S3)","author":"Yamazaki","year":"2022","journal-title":"Hemasphere"},{"issue":"12","key":"2024081315054528800_bib114","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3324\/haematol.2022.280758","article-title":"Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study","volume":"107","author":"Xu","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"2024081315054528800_bib115","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3324\/haematol.2023.284022","article-title":"Uniform conditioning regardless of donor in bone marrow transplantation for severe aplastic anemia","volume":"109","author":"DeZern","year":"2024","journal-title":"Haematologica"},{"issue":"25","key":"2024081315054528800_bib116","first-page":"3031","article-title":"Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia","volume":"141","author":"DeZern","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2024081315054528800_bib117","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3324\/haematol.2018.206540","article-title":"Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study","volume":"104","author":"Rogers","year":"2019","journal-title":"Haematologica"},{"key":"2024081315054528800_bib118","unstructured":"National Comprehensive Cancer Network\n          . NCCN guidelines for patients. Myelodysplastic Syndromes. Accessed 12 March 2024. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/mds-patient.pdf."},{"issue":"1","key":"2024081315054528800_bib119","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminhematol.2018.05.016","article-title":"Acquired and germline predisposition to bone marrow failure: diagnostic features and clinical implications","volume":"56","author":"Kallen","year":"2019","journal-title":"Semin Hematol"},{"issue":"11","key":"2024081315054528800_bib120","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3324\/haematol.2016.149476","article-title":"Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients","volume":"101","author":"Keel","year":"2016","journal-title":"Haematologica"},{"issue":"7651","key":"2024081315054528800_bib121","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \u201cquality of evidence\u201d and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/3946\/2237960\/blooda_adv-2023-011642-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/15\/3946\/2237960\/blooda_adv-2023-011642-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T15:17:35Z","timestamp":1723562255000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/15\/3946\/515904\/Modified-Delphi-panel-consensus-recommendations"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":121,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011642","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}